Radioimmunotherapy and secondary leukemia: a case report.
Magni M
Leuk Res. 2009 May 15;34(1):e1-4. doi: 10.1016/j.leukres.2009.04.028
Efficacy and safety of high-dose chemotherapy with in vivo purged auto-SCT in relapsed follicular lymphoma: long-term follow-up.
Magni M
Bone Marrow Transplant. 2009 Oct 12;45(6):1119-20. doi: 10.1038/bmt.2009.294
Comparative assessment of telomere length before and after hematopoietic SCT: role of grafted cells in determining post-transplant telomere status.
Ruella M
Bone Marrow Transplant. 2009 Oct 19;45(3):505-12. doi: 10.1038/bmt.2009.297
Germ-line mutation of the NRAS gene may be responsible for the development of juvenile myelomonocytic leukaemia.
De Filippi P
Br J Haematol. 2009 Sep 22;147(5):706-9. doi: 10.1111/j.1365-2141.2009.07894.x
A computational approach to compare microvessel distributions in tumors following antiangiogenic treatments.
Righi M
Lab Invest. 2009 Aug 3;89(9):1063-70. doi: 10.1038/labinvest.2009.76
Absorbed dose and biologically effective dose in patients with high-risk non-Hodgkin’s lymphoma treated with high-activity myeloablative 90Y-ibritumomab tiuxetan (Zevalin).
Chiesa C
Eur J Nucl Med Mol Imaging. 2009 May 20;36(11):1745-57. doi: 10.1007/s00259-009-1141-x
Haploidentical stem cell transplantation after a reduced-intensity conditioning regimen for the treatment of advanced hematologic malignancies: posttransplantation CD8-depleted donor lymphocyte infusions contribute to improve T-cell recovery.
Dodero A
Blood. 2009 Feb 11;113(19):4771-9. doi: 10.1182/blood-2008-10-183723
High-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting in mantle cell lymphoma: a 10-year update of the R-HDS regimen.
Magni M
Bone Marrow Transplant. 2008 Oct 27;43(6):509-11. doi: 10.1038/bmt.2008.349
Vaccination with autologous tumor-loaded dendritic cells induces clinical and immunologic responses in indolent B-cell lymphoma patients with relapsed and measurable disease: a pilot study.
Di Nicola M
Blood. 2008 Sep 22;113(1):18-27. doi: 10.1182/blood-2008-06-165654
High-dose yttrium-90-ibritumomab tiuxetan with tandem stem-cell reinfusion: an outpatient preparative regimen for autologous hematopoietic cell transplantation.
Devizzi L
J Clin Oncol. 2008 Oct 14;26(32):5175-82. doi: 10.1200/JCO.2008.16.8294